Biopharma sales slightly lower than expected at Novo Nordisk
While Novo Nordisk increased its biopharma sales in 2021 compared to 2020, the Danish pharmaceutical giant did not manage to beat the estimations made by analysts.
by marketwire, translated by daniel pedersen
Novo Nordisk’s biopharma arm saw sales grow to DKK 4.7bn (USD 713.9m) in the fourth quarter of 2021, up from DKK 4.4bn (USD 668.35m) the same period last year, according to Novo’s financial figures, which were released on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Obesity business grows at Novo Nordisk despite Wegovy woes
For subscribers
.jpg&w=384&q=75)
